Scarica l'app Stockscreener
2.00
1.96%
-0.04
Dopo l'orario di chiusura:
2.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$2.04
Aprire:
$2.04
Volume 24 ore:
675.06K
Relative Volume:
0.94
Capitalizzazione di mercato:
$43.74M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-0.3257
EPS:
-6.14
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
+25.00%
1M Prestazione:
-9.09%
6M Prestazione:
-0.50%
1 anno Prestazione:
+418.81%
Intervallo 1D:
$1.87
$2.04
Intervallo di 1 settimana:
$1.59
$2.12
Portata 52W:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
2.00 | 44.61M | 1.38M | -179.05M | -155.03M | -6.14 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Trend Review: How institutional buying supports BioXcel Therapeutics Inc. stockJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - ulpravda.ru
Will BioXcel Therapeutics Inc. stock attract ESG investorsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru
Is BioXcel Therapeutics Inc. (BX20) stock undervalued historicallyJuly 2025 Breakouts & Fast Moving Stock Trade Plans - ulpravda.ru
What insider trading reveals about BioXcel Therapeutics Inc. stockTrade Risk Assessment & Fast Entry Momentum Alerts - ulpravda.ru
How robust is BioXcel Therapeutics Inc. (BX20) stock financial positionMACD Histogram Signals & Maximize Returns With Insights - ulpravda.ru
BioXcel Seeks FDA Nod For At-Home Use Of IGALMI In Bipolar And Schizophrenia Agitation - Nasdaq
BioXcel plans FDA submission for at-home agitation treatment By Investing.com - Investing.com Nigeria
BioXcel plans FDA submission for at-home agitation treatment - Investing.com India
BTAI FinancialsIncome Statement - Quiver Quantitative
BioXcel Therapeutics, Inc. Plans Supplemental NDA Submission for IGALMI® Approval for At-Home Use in Treating Agitation Associated with Bipolar Disorders and Schizophrenia - Quiver Quantitative
Drugmaker moves to bring at-home relief for bipolar agitation - Stock Titan
BioXcel Therapeutics enacts 1-for-16 reverse stock split - MSN
BioXcel Therapeutics (BTAI) price target decreased by 26.17% to 16.12 - MSN
Will BioXcel Therapeutics Inc. stock see insider buying2025 Sector Review & Real-Time Chart Breakout Alerts - moha.gov.vn
Vipin Agarwal Net Worth (2025) - GuruFocus
What MACD trends signal for BioXcel Therapeutics Inc. (BX20) stockWeekly Market Report & Community Driven Trade Alerts - Улправда
EPS Watch: How robust is BioXcel Therapeutics Inc. (BX20) stock financial position2025 Earnings Surprises & AI Powered Market Entry Strategies - Улправда
Gap Down: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryWeekly Gains Report & Daily Momentum Trading Reports - Улправда
Can BioXcel Therapeutics Inc. stock maintain growth trajectoryEarnings Overview Summary & Verified Swing Trading Watchlist - Улправда
Risk Off: Will BioXcel Therapeutics Inc. stock see insider buying2025 Growth vs Value & AI Driven Stock Reports - Улправда
BioXcel Therapeutics (BTAI) Stock Analysis Report | Financials & Insights - Benzinga
Loss Report: Will BioXcel Therapeutics Inc. stock see insider buyingJuly 2025 Update & Daily Volume Surge Trade Alerts - Улправда
BioXcel Therapeutics Earnings Notes - Trefis
BioXcel Therapeutics holds annual stockholders meeting - MSN
BioXcel Therapeutics Holds Annual Stockholders Meeting - TipRanks
BioXcel Therapeutics (NASDAQ: BTAI) wins approval for reverse stock split plan - Stock Titan
BTAI: All proposals, including director elections and a reverse split amendment, were approved - TradingView — Track All Markets
BioXcel Therapeutics Inc To Host Virtual Roundtable with Leading Medical Experts Transcript - GuruFocus
Aug Decliners: What MACD trends signal for BioXcel Therapeutics Inc BX20 stockJuly 2025 Snapshot & Advanced Swing Trade Entry Alerts - moha.gov.vn
Can BioXcel Therapeutics Inc. (BX20) stock sustain free cash flowQuarterly Growth Report & Weekly High Return Opportunities - Newser
What Analysts Think Is Changing The Story For BioXcel Therapeutics Now - Yahoo Finance
Can BioXcel Therapeutics Inc. stock beat analyst upgrades2025 Biggest Moves & Real-Time Sentiment Analysis - Newser
Is BioXcel Therapeutics Inc. (BX20) stock a fit for income portfoliosM&A Rumor & Fast Entry Momentum Alerts - Newser
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions - The Manila Times
Award-Winning Journalist Anjalee Khemlani to Host Virtual - GlobeNewswire
BioXcel Therapeutics (BTAI) hosts Dec. 8 virtual panel on at-home agitation treatment - Stock Titan
What is the fair value of BioXcel Therapeutics Inc. stock nowJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
Is BioXcel Therapeutics Inc. (BX20) stock worth holding before Fed meeting2025 Winners & Losers & Technical Entry and Exit Tips - Newser
Can BioXcel Therapeutics Inc. stock resist market sell offsTrade Volume Report & Technical Pattern Alert System - BỘ NỘI VỤ
FDA Approves New Indication for BioXcel Therapeutics' Igalmi (BT - GuruFocus
Why BioXcel Therapeutics Inc. (BX20) stock could be next leaderMarket Volume Summary & AI Enhanced Trading Alerts - newser.com
Can BioXcel Therapeutics Inc. stock deliver consistent earnings growthEarnings Recap Summary & Consistent Return Investment Signals - newser.com
Is BioXcel Therapeutics Inc. stock attractive after correctionQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Why BioXcel Therapeutics Inc. (BX20) stock is listed among top recommendationsEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Will BioXcel Therapeutics Inc. stock see PE expansionJuly 2025 Earnings & Long Hold Capital Preservation Tips - newser.com
Can BioXcel Therapeutics Inc. stock beat market expectations this quarterTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
BioXcel Therapeutics Inc. (BTAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is BioXcel Therapeutics Inc. (BX20) stock vulnerable to rate hikesChart Signals & Daily Entry Point Alerts - newser.com
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.41%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):